Cooperative Agreement UG3CA290302

Award Date 6/13/24
Completion Date 5/31/26
Dollars Obligated $790K
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $606,993 to Emory University to conduct research aimed at improving immune modulation as a strategy to prevent the progression of smoldering multiple myeloma (SMM) to clinical multiple myeloma (MM). The key objectives are to: Evaluate whether properties of immune cells at baseline in SMM correlate with the risk of progression to clinical MM. Assess changes in circulating and...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $281,606 to New York University School of Medicine to conduct research aimed at harnessing gut-derived bacteria to drive anti-tumor immunity in lung cancer. The 5-year project, led by Dr. Rabi Upadhyay, an Assistant Professor at NYU, will investigate the mechanism by which certain gut commensals can trigger systemic anti-tumor immune responses, even in the absence...
This $621,156 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania aims to identify novel regulators of endoplasmic reticulum (ER) homeostasis in malignant plasma cells that can be targeted to induce cell death or prevent upstream events fostering multiple myeloma (MM), a deadly plasma cell malignancy. The key objectives are to: 1) inhibit P2RX receptor signaling in premalignant and malignant...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $644,190 to the Mayo Clinic to conduct research on "Metabolic Strategies to Eradicate Premalignant Clonal Plasma Cells and Prevent the Development of Multiple Myeloma." The award period runs from September 1, 2024 to August 31, 2026. The grant supports the Mayo Clinic's expertise in cancer research, clinical trials, and translational medicine to...
This Project Grant award of $210,600 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the role of "public" immunoglobulin A (IgA) antibodies in regulating the gut microbiome and inflammation in persons living with HIV-1 (PWH). The key objectives are to: Prepare recombinant "public" IgA clonotypes found in HIV-1-uninfected individuals and PWH, and examine...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research to investigate how the immune system, specifically B cells, establish tolerance to commensal (beneficial) microbes. The $379,609 award to the University of Pittsburgh will support the development of genetically-modified mouse models to track the responses of B cells specific to a model commensal antigen. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy. The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and...
This $620,521 Project Grant award from the National Cancer Institute's (NCI) Cancer Detection and Diagnosis Research program (CFDA 93.394) supports an integrated mathematical modeling approach to understand how the aging bone ecosystem drives multiple myeloma evolution and treatment response. Key objectives include: Using spatial transcriptomic data from young and aged mice to "age" a hybrid cellular automata (HCA) mathematical model of the multiple myeloma-bone microenvironment....
This $674,440 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) federal grant program. The grant supports research at the University of Miami to comprehensively define the clinical impact of myeloma-defining genomic and immune events among myeloma precursor conditions (MPCs), in order to differentiate benign from malignant MPCs. The study will utilize novel single-cell whole genome sequencing (scWGS) to characterize the subclonal...

TARGETING MICROBIAL TRIGGERS OF GAMMOPATHY FOR IMMUNOPREVENTION - ABSTRACT: MULTIPLE MYELOMA (MM) IS AN INCURABLE PLASMA CELL TUMOR PRECEDED BY A DEFINED PRENEOPLASTIC STATE TERMED AS MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS). STRATEGIES TO EFFECTIVELY INTERCEPT/PREVENT CLINICAL MALIGNANCY REMAIN AN UNMET NEED AND ARE THE FOCUS OF THIS APPLICATION. CHANGES IN MICROBIAL COMMUNITIES HAVE BEEN EXTENSIVELY STUDIED IN THE CONTEXT OF CANCER OUTCOMES AND THERAPY. HOWEVER, VERY FEW CAUSAL RELATIONSHIPS BETWEEN SPECIFIC MICROBES AND HUMAN MALIGNANCIES HAVE BEEN DEFINED, AND SUITABLE MODELS TO STUDY THESE INTERACTIONS ARE LACKING. IT IS INCREASINGLY APPRECIATED THAT MM/MGUS ORIGINATE IN THE SETTING OF PRIOR CHRONIC INFLAMMATION AND B CELL ACTIVATION, BUT THE UNDERLYING TRIGGERS REMAIN UNKNOWN. THIS APPLICATION INVOLVES THREE PIS (DHODAPKAR, FLAVELL, PALM) WITH COMPLEMENTARY EXPERTISE AND A TRACK RECORD OF PRODUCTIVE COLLABORATION. THE APPLICATION IS BASED ON EXCITING PRELIMINARY DATA DESCRIBING THE DISCOVERY OF A COMMENSAL MICROBIAL SPECIES THAT DIRECTLY ENGAGE SEVERAL HUMAN MM-ASSOCIATED B-CELL RECEPTORS. THIS IS SUPPORTED BY DATA FROM NEW HUMANIZED MODELS TO STUDY INTERACTIONS BETWEEN THE HUMAN IMMUNE SYSTEM AND MICROBIAL COMMUNITIES IN VIVO. THE PROPOSAL ALSO UTILIZES BIOSPECIMENS FROM MGUS PATIENTS TREATED WITH A SHORT COURSE OF ANTIBIOTICS TO REDUCE PATHOGENIC BACTERIA. STUDIES PROPOSED IN THIS APPLICATION WILL CHARACTERIZE THE FULL SPECTRUM OF HUMAN GUT MICROBES THAT CAN POTENTIALLY SERVE AS ANTIGENIC TRIGGERS FOR HUMAN B CELLS AND MGUS. IT WILL ALSO EVALUATE CAUSAL RELATIONSHIPS BETWEEN SPECIFIC MICROBES AND ACTIVATION OF HUMAN B CELLS AS WELL AS MGUS CELLS UTILIZING NEWLY DEVELOPED MODELS. FINALLY, IT WILL EVALUATE HOW MICROBIAL MANIPULATION IN MGUS PATIENTS CAN IMPACT THE INFLAMMATORY MICROENVIRONMENT KNOWN TO BE PRESENT AND IMPLICATED IN THE PATHOGENESIS OF MGUS AND ITS TRANSITION TO CLINICAL MALIGNANCY. TOGETHER, THESE STUDIES MAY LEAD TO NOVEL APPROACHES FOR IMMUNE-PREVENTION OF CLINICAL MM BY TARGETING THE UNDERLYING PRECURSOR STATES SUCH AS MGUS. INSIGHTS FROM THESE STUDIES MAY ALSO HAVE IMPLICATIONS FOR INTERACTIONS BETWEEN SPECIFIC MICROBES AND HUMAN B CELLS, BROADLY IMPACTING HUMAN AUTOIMMUNITY AND CANCER IMMUNOTHERAPY.

Posted 6/13/24, 12:00 AM